Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.

CONCLUSION: Patients with a serum testosterone level ≥5 ng/dl were more likely to receive therapeutic benefits from AR-targeted therapy compared to those with serum testosterone levels <5 ng/dl. However, even for those with a very low serum testosterone level, the efficacy of abiraterone was slightly higher than that of enzalutamide. Therefore, serum testosterone level is a useful biomarker for informing treatment selection for CRPC.
PMID: 31103335 [PubMed - as supplied by publisher]

Source: Urologic Oncology - May 15, 2019 Category: Urology & Nephrology Authors: Hashimoto K, Tabata H, Shindo T, Tanaka T, Hashimoto J, Inoue R, Muranaka T, Hotta H, Yanase M, Kunishima Y, Takahashi A, Masumori N, Sapporo Medical University Urologic Oncology Consortium (SUOC) Tags: Urol Oncol Source Type: research